EGFR and lung carcinoma: For instance, mutations in the epidermal growth factor receptor (EGFR) predict the response to tyrosine kinase inhibitors in lung cancer (Mok et al., 2009; Paez et al., 2004) and the genotyping of the EGFR in plasma is validated and approved as a diagnostic implement in the clinical setting (Planchard et al., 2018; U.S. Food and Drug Administration (2016).